Cyclacel Pharmaceuticals, Inc. Sustainability Profile
Cyclacel Pharmaceuticals, Inc., a prominent player in the biotechnology sector, is headquartered in the United States. Founded in 1996, the company has made significant strides in developing innovative cancer therapies, particularly focusing on cell cycle regulation and apoptosis. With a strong emphasis on research and development, Cyclacel is dedicated to advancing its proprietary drug candidates, including the unique oral treatment, fadraciclib, which targets specific cancer pathways. Operating primarily in the oncology space, Cyclacel has established itself as a leader in the development of novel therapeutics that address unmet medical needs. The company’s commitment to scientific excellence has garnered recognition within the industry, positioning it favourably among peers. With a robust pipeline and strategic partnerships, Cyclacel Pharmaceuticals continues to push the boundaries of cancer treatment, striving to improve patient outcomes globally.
DitchCarbon Score
How does Cyclacel Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cyclacel Pharmaceuticals, Inc.'s score of 23 is lower than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cyclacel Pharmaceuticals, Inc.'s reported carbon emissions
Cyclacel Pharmaceuticals, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Cyclacel Pharmaceuticals may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. As the pharmaceutical industry increasingly prioritises sustainability, it remains essential for companies like Cyclacel to consider developing and communicating their climate strategies to align with industry standards and stakeholder expectations.
How Carbon Intensive is Cyclacel Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Cyclacel Pharmaceuticals, Inc.'s Location?
Cyclacel Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Cyclacel Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
